RADIATION THERAPY ONCOLOGY GROUP
RTOG 0417
A PHASE II STUDY OF AN ORAL EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR TKI) ZD 1839 (IRESSA(r)) IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA
RTOG 0417
A PHASE II STUDY OF AN ORAL EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR TKI) ZD 1839 (IRESSA(r)) IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA
Optional Brachtherapy Imaging Study for RTOG 0417
- Brachytherapy Imaging Guidelines (draft, 11/19/2004)
- Digital Data Submission Procedure
- Facility Questionnaire (see RPC credentialing documents)
- Digital Data Submission Information Form
- ATC Compliant Treatment Planning Systems
Back to protocols
